The AML treatment landscape has significantly changed in recent years with the approval of
targeted therapies in the front-line and relapsed/refractory settings, including inhibitors of …

The nucleophosmin (NPM1) gene encodes for a multifunctional chaperone protein that is
localized in the nucleolus but continuously shuttles between the nucleus and cytoplasm …

The dysregulation of developmental and stem cell–associated genes is a common
phenomenon during cancer development. Around half of patients with acute myeloid …

Mutations in NPM1, also known as nucleophosmin-1, B23, NO38, or numatrin, are seen in
approximately one-third of patients with acute myeloid leukaemia (AML). A plethora of …

Somatic mutations in the nucleophosmin (NPM1) gene occur in approximately 30% of de
novo acute myeloid leukemias (AMLs) and are relatively enriched in normal karyotype …

Acute myeloid leukemia (AML) is a common hematologic malignancy that is considered to
be a disease of aging, and traditionally has been treated with induction chemotherapy …

Background: Chronic myeloid leukemia is a hematological malignancy characterized by the
abnormal proliferation of leukemic cells. Despite significant progress with tyrosine kinase …

The nucleophosmin (NPM1) gene encodes for the most abundant nucleolar protein. Thanks
to its property to act as histone chaperone and to shuttle between the nucleus and …

Despite advances in the clinical management of childhood acute myeloid leukemia (AML)
during the last decades, outcome remains fatal in approximately one third of patients …

Acute myeloid leukemia (AML) is a rare subtype of acute leukemia in the pediatric and
adolescent population but causes disproportionate morbidity and mortality in this age group …